Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to a specific transaction notification and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely discloses an increase in American Depositary Receipts (ADRs) held by a specific individual.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports a transaction where Mr. E J Gray increased his interest in ADRs by 16,526 units at a price of $46.13 per ADR following the re-investment of a dividend paid on January 5, 2012.
Key Facts for Investor Verification
- Transaction Date: January 10, 2012.
- Individual Involved: Mr. E J Gray.
- Transaction Type: Increase in ADR holdings via dividend re-investment.
- Volume: 16,526 ADRs.
- Price: $46.13 per ADR.
- Regulatory Basis: Disclosure and Transparency Rule 3.1.4R(1)(a).